News Bulletin

Thuesday, April 14th, 2026

Morning Edition

 

Economic Numbers:

Time

Event

Actual

Forecast

Previous

Tuesday, April 14, 2026

5:00

IEA Monthly Report

 

 

 

6:00

NFIB Small Business Optimism (Mar)

95.8

97.8

98.8

6:00

IMF Meetings

 

 

 

8:10

ADP Employment Change Weekly

 

 

26.00K

8:30

PPI (MoM) (Mar)

 

1.10%

0.70%

8:30

Core PPI (MoM) (Mar)

 

0.40%

0.50%

8:30

PPI ex. Food/Energy/Transport (YoY) (Mar)

 

 

3.50%

8:30

PPI (YoY) (Mar)

 

4.60%

3.40%

8:30

PPI ex. Food/Energy/Transport (MoM) (Mar)

 

 

0.50%

8:30

Core PPI (YoY) (Mar)

 

4.20%

3.90%

8:55

Redbook (YoY)

 

 

7.60%

9:45

Fed Goolsbee Speaks

 

 

 

12:10

Fed Goolsbee Speaks

 

 

 

12:45

Fed Vice Chair for Supervision Barr Speaks

 

 

 

13:00

FOMC Member Barkin Speaks

 

 

 

13:00

Fed Collins Speaks

 

 

 

16:30

API Weekly Crude Oil Stock

 

 

3.719M

 

Indices
 

 

CLOSE

50 DMA

200 DMA

DJIA

48,218.25

47,981.76

46,868.18

NASDAQ

23,183.74

22,491.33

22,427.17

S&P 500

6,886.24

6,753.19

6,668.80

 

Earnings Calendar:

(EPS: Earning Per Share / Rev: Revenue / Mkt Cap : market Capital/ BMO : Before Market Opening /AMC : After Market Close)

NAME

COMPANY

Mkt CAP

EPS (Forcast)

EPS (Actual)

Revenue (Forcast)

Revenue (Actual)

Time

UNTY

Unity Bancorp

$559.62M

1.38

(+1.82%) +$1.4

$33.59M

 

 

QUCY

Quantum Cyber

$5.54M

-1.01

 

$670.00K

 

 

OGI

Organigram Global

$191.31M

>-$0.01

 

$52.06M

 

 

LOVFF

Cannara Biotech

$138.26M

0.04

(-60%) +$0.015

$22.99M

(+18.09%) +$27.146M

BMO

THCH

TH International

$67.48M

-0.19

 

$52.46M

 

BMO

BSVN

Bank7

$407.14M

1.02

 

$23.56M

 

BMO

AGFMF

AGF Management B NV

C$932.87M

0.36

(-45.45%) +$0.196

$112.02M

 

BMO

DTST

Data Storage

$29.99M

-0.09

 

$400.00K

 

BMO

CREX

Creative Realities

$36.40M

-0.03

(-536.36%) -$0.21

$22.27M

(+7.39%) +$23.92M

BMO

RENT

Rent the Runway

$188.32M

 

 

 

 

BMO

HOVR

New Horizon Aircraft

$69.92M

-0.11

 

0

 

BMO

ACI

Albertsons Companies

$8.88B

0.43

 

$20.47B

 

BMO

KMX

CarMax

$6.62B

0.2

(-533.67%) -$0.85

$5.73B

(+3.71%) +$5.946B

BMO

BLK

BlackRock

$163.04B

11.65

(+20.67%) +$14.06

$6.55B

(+2.25%) +$6.698B

BMO

WFC

Wells Fargo

$263.51B

1.58

(+1.14%) +$1.6

$21.79B

(-1.57%) +$21.45B

BMO

C

Citigroup

$217.60B

2.63

 

$23.53B

 

BMO

JPM

JPMorgan Chase

$835.73B

5.45

(+8.97%) +$5.94

$49.13B

(+1.37%) +$49.8B

BMO

JNJ

Johnson & Johnson

$574.36B

2.68

(-20.06%) +$2.14

$23.61B

(+1.89%) +$24.062B

AMC

GLOO

Gloo Holdings, Inc. Class A

$411.25M

-0.45

 

$31.57M

 

AMC

EQBK

Equity Bancshares

$973.20M

1.11

 

$82.41M

 

AMC

MAMA

Mama's Creations

$633.79M

0.04

 

$52.64M

 

AMC

SURG

SurgePays

$15.70M

-0.16

 

$21.16M

 

AMC

XTIA

XTI Aerospace

$66.95M

-0.34

(0%) -$0.34

$14.50M

 

AMC

 

Market News:

Albertsons Companies Inc. (NYSE:ACI) reported its fourth quarter results on Tuesday, with earnings topping expectations but revenue below the consensus estimate.

Adjusted earnings per share came in at $0.48, surpassing the analyst estimate of $0.43. Revenue of $20.3 billion fell short of the $20.49 billion consensus. The grocer's revenue increased from $18.8 billion in the prior-year period, which included one fewer week than the current quarter.

 

 

Clearmind Medicine Inc. (Nasdaq:CMND) shares rose 40% after the company announced its CMND-100 drug candidate met the primary endpoint in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder.

The clinical trial evaluated CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate. Results from the third cohort showed a high safety profile at the higher dosage administered to date, with the drug candidate being well tolerated and no serious adverse events reported.

 

 

Albertsons (ACI) declared a quarterly dividend of $0.17 per share, or $0.68 annualized. This is a 13.3% increase from the prior dividend of $0.15.

 

 

Travere Therapeutics (NASDAQ:TVTX) shares jumped 44% Tuesday following FDA approval of FILSPARI for the treatment of focal segmental glomerulosclerosis, a rare kidney disease.

The FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with FSGS without nephrotic syndrome. FILSPARI becomes the first and only medicine approved by the FDA for the treatment of FSGS, expanding beyond its existing approval for IgA nephropathy into a second rare kidney disease.

 

 

Lucid Group Inc (NASDAQ:LCID) shares rose 11% Tuesday after the electric vehicle maker announced $750 million in new investments and a major expansion of its robotaxi partnership with Uber.

Ayar Third Investment Company, an affiliate of the Public Investment Fund, committed to purchase $550 million of Lucid’s convertible preferred stock. Uber agreed to invest an additional $200 million, bringing its total investment in Lucid to $500 million.

 

 

Johnson & Johnson (NYSE:JNJ) reported its first-quarter results on Tuesday, exceeding analyst expectations.

Adjusted earnings per share came in at $2.70, beating the consensus estimate of $2.68 by $0.02. Revenue reached $24.1 billion, surpassing the $23.61 billion analyst estimate and representing a 9.9% increase from $21.9 billion in the same quarter last year.

For internal use only